58 results about "Acetaminophen" patented technology

This invention discloses a polyethylene glycol-modified magnesium boride nanosheet and its application in treating acute liver failure and hepatic encephalopathy caused by acetaminophen. The nanosheet uses magnesium boride nanosheets as a core, with polyethylene glycol modified on the surface to improve biocompatibility. The nanosheet of this invention exhibits good antioxidant properties and can be used to prepare nanomedicines for treating acute liver failure and / or hepatic encephalopathy caused by acetaminophen. It generates reducing hydrogen gas through a hydrolysis reaction, effectively scavenging reactive oxygen species at the site of liver failure, thereby inhibiting inflammatory responses and effectively alleviating symptoms caused by acute liver failure.

The invention discloses synthesis and pharmacodynamic toxicological research of an acetaminophen derivative, the acetaminophen derivative has a structure as shown in the following formula (I) or a pharmaceutically acceptable salt thereof, in the formula (I), R1 is selected from-OH, F, Cl or Br; r2 is selected from S or O; when R2 is O, R1 is not-OH; and preferably, R2 is S. The invention designs and synthesizes a series of APAP-based novel derivatives from the perspective of changing the metabolic pathway of the drug by carrying out reasonable drug modification on APAP, and reduces the toxic and side effects of the original drug while exerting the biological activity similar to or higher than that of the original drug.

The invention provides an electrode for an implantable biosensor and application of the electrode, a conducting layer of the electrode is located on an insulating substrate of the biosensor, a sensing layer and a limiting layer are sequentially arranged on the conducting layer of the electrode, the sensing layer comprises enzyme required by reaction, and the sensing layer further comprises cationic polymer. The biosensor provided by the invention realizes good linear correlation of testing under low potential, obviously reduces interference of acetaminophen and other interfering substances on test signals under the condition of low-potential testing, and improves the accuracy of detection.

Disclosed in the present application are a method and drug for preventing or treating a neurodegenerative disease, whereby a therapeutically effective amount of gliclazide or a pharmaceutically acceptable salt thereof or a combination of gliclazide or a pharmaceutically acceptable salt thereof and acetaminophen or a pharmaceutically acceptable salt thereof is used or comprised. The method and drug of the present invention can significantly alleviate symptoms such as hyposmia, cognitive dysfunction, and psychiatric symptoms in patients with neurodegenerative diseases that cannot be treated with existing drugs, and can be particularly used for controlling the progression of neurodegenerative diseases.

Pharmaceutical formulations containing acetaminophen and sulfoalkyl ether cyclodextrin are described. The formulation includes acetaminophen; and sulfoalkyl ether cyclodextrin, wherein the molar ratio of sulfoalkyl ether cyclodextrin to acetaminophen is in the range of about 0.01 to about 2. The formulations can be prepared in an injectable form for mitigating or treating fever or alleviating pain in a patient.

The invention discloses an acetaminophen disinfection by-product as well as a preparation method and application thereof, belongs to the technical field of environmental chemistry and organic synthesis, and particularly relates to two acetaminophen disinfection by-products, namely a compound P186 and a compound P220. According to the method, a column chromatography gradient elution system is established by simulating the reaction of acetaminophen and sodium hypochlorite during water disinfection, and analysis instruments such as a high performance liquid chromatography-quadrupole-time-of-flight mass spectrometer, high performance liquid chromatography, carbon-13 nuclear magnetic resonance, hydrogen-1 nuclear magnetic resonance and a Fourier transform infrared instrument are combined, so that the content of acetaminophen in water is detected, and the content of acetaminophen in water is detected. And analyzing and identifying the structures and the purities of the compound P186 and the compound P220. The method can provide standard samples and technical support for the conversion mechanism, toxicity evaluation and pollution prevention and control of the acetaminophen disinfection by-product in the environment.

To provide a solid composition containing acetaminophen having sufficient hardness. A solid composition comprising acetaminophen, glycine, and licorice.

The application belongs to the technical field of biological medicine, and particularly relates to application of a METTL3 inhibitor in preparation of a medicine for treating drug-induced liver injury; the METTL3 inhibitor comprises STM2457 or JNJ64619178; the drug-induced liver injury is acetaminophen-induced acute liver injury. It is found for the first time that the METTL3 inhibitor STM2457 or JNJ64619178 has a significant curative effect on treatment of acetaminophen-induced drug-induced liver injury, STM2457 or JNJ64619178 can effectively alleviate acute liver tissue injury caused by acetaminophen, inhibit further apoptosis and necrosis of hepatocytes, help promote recovery of liver injury, and the treatment effect is better than that of a traditional medicine N-acetylcysteine, thus providing a new treatment means for acetaminophen-induced drug-induced liver injury and expanding the clinical application range of the inhibitor.

The invention belongs to the technical field of acetaminophen medicine synthesis, and particularly relates to a preparation method of acetaminophen, which is characterized in that acetaminophen and glacial acetic acid are subjected to one-step amidation reaction in a negative-pressure low-temperature reaction system to synthesize acetaminophen. The method solves the problems of high acetaminophen preparation temperature, easy raw material oxidation, low crude product quality, high cost and environmental protection potential safety hazard.

The invention belongs to the technical field of medicines, and particularly relates to application of a pharmaceutical composition in preparation of a medicine for treating oral ulcer. According to the application of the medicine composition in preparation of the medicine for treating the oral ulcer, through the synergistic effect of aspirin, acetaminophen and caffeine, the effects of resisting inflammation, easing pain and promoting ulcer healing can be achieved at the same time, the problem that in the prior art, inflammation control and pain relief are difficult to be effectively achieved at the same time is solved, and the medicine composition is worthy of popularization and application. The traditional Chinese medicine composition has the advantages that the oral mucosa inflammatory factors IL-2, IL-6 and TNF-alpha expression conditions can be obviously reduced, epithelial regeneration related pathway genes and expression are promoted to be increased, activated Mmp2 is inhibited, Bcl2 gene expression is increased, cell apoptosis signals are reduced, oral mucosa ulcer is relieved, the inflammatory state of oral ulcer is improved from the molecular level, and ulcer healing is accelerated.

This invention discloses a method for degrading acetaminophen in water using PCN-224-activated persulfate. The method utilizes the PCN-224 photocatalyst to activate persulfate and degrade acetaminophen-containing water. The PCN-224 photocatalyst is prepared from tetrakis(4-carboxyphenyl)porphyrin and zirconium oxychloride through a hydrothermal reaction at 65℃–80℃. The PCN-224 photocatalyst of this invention possesses abundant microporous and mesoporous structures and numerous functional groups, which not only facilitates the rapid adsorption of acetaminophen and the rapid activation of persulfate but also enhances the activation effect of persulfate, ultimately achieving efficient and complete degradation of acetaminophen. The method of this invention has advantages such as simple process, convenient operation, good removal effect, wide applicability, and no risk of secondary pollution, making it of practical significance for the treatment of acetaminophen wastewater in the environment.

The invention discloses a new application of hyodeoxycholic acid, namely an application of hyodeoxycholic acid in preparation of a medicine for preventing or treating liver injury. A mouse drug-induced liver injury model is established through acetaminophen, ALT, AST, gamma-GT and the like in serum of a mouse given with hyodeoxycholic acid are remarkably reduced, and the liver function is basically recovered; pathological histology shows that the liver form and structure tend to be normal; the levels of inflammatory factors IL-1beta, IL-6 and TNF-alpha in the liver are remarkably reduced, and the inflammatory response of the liver is relieved; meanwhile, the levels of GSH, SOD and the like in liver tissues are improved, MDA accumulation is reduced, and liver oxidative stress is weakened. Therefore, the hyodeoxycholic acid can effectively relieve the APAP-induced drug-induced liver injury, and has great potential in development of liver protection drugs.

The application relates to the technical field of pharmaceutical chemistry, and discloses a flurbiprofen ester enantiomer prodrug compound, a preparation method thereof, a pharmaceutical composition and purposes, the compound is (R)-AF377 or (S)-AF377, is formed by covalently connecting a carboxyl of (R)-flurbiprofen, (S)-flurbiprofen and a phenolic hydroxyl of acetaminophen through an ester bond, corresponding chiral carbons are R configuration and S configuration respectively, and structures are shown in formula (I) and formula (II). The application further provides a preparation method of the compound, a pharmaceutical composition containing the compound and purposes of the compound in pain, inflammation or fever treatment. The compound has high optical purity, releases an active ingredient in the liver, (S)-AF377 has synergistic anti-inflammatory analgesic activity, (R)-AF377 has independent analgesic activity, can reduce side effects of single drug use, improves bioavailability, and provides a new drug selection for treatment of mild to moderate inflammatory pain.

This invention provides a coumarin-chalcone hybrid compound, its preparation method, and its applications. The structure of the coumarin-chalcone hybrid compound is shown in Formula I. The coumarin-chalcone hybrid compound provided by this invention has a simple and easy synthesis process, readily available raw materials, and can significantly activate the transcriptional activity of Nrf2 at both the cellular and animal levels. It exhibits high safety, good cell membrane permeability, and can be taken orally. After oral administration, it primarily results in high exposure in the liver and can effectively alleviate liver damage caused by acetaminophen and alcohol.

The invention discloses a compound paracetamol and amantadine hydrochloride capsule containing caffeine microcapsules, which relates to the technical field of medicines and comprises paracetamol, amantadine hydrochloride, calculus bovis factitius, pharmaceutic adjuvants and functional microcapsule units. The functional microcapsule unit has a three-layer structure: a core material taking caffeine and microcrystalline cellulose as a core, an ethyl cellulose controlled release layer and a quick release layer containing chlorpheniramine maleate. According to the structure, time sequence controlled release of drugs is achieved by synthesizing a polymer coating material, chlorpheniramine maleate is quickly released when encountering gastrointestinal fluid to quickly resist allergy, and caffeine starts to be slowly released after being effectively delayed to the intestinal environment, so that the time when the plasma concentration reaches the peak tends to be synchronous with the time when chlorpheniramine maleate reaches the peak; the drowsiness side effect can be effectively resisted.

A mochi containing functional food or pharmaceutical ingredients, said mochi comprising: glutinous rice, trehalose, water, gelatin and / or pectin and / or agar and / or carrageenan and / or collagen and / or other gelling agents, essences, flavors and other auxiliary materials which affect the organoleptic properties and pH of the mochi, functional ingredients, pH regulators, and additives, wherein the functional components can also contain glucose and sugar, or fiber, or protein or polyhydric alcohol, and the functional components can be microencapsulated and can contain amino acid or omega 3, omega 9 or melatonin for improving sleep, or ibuprofen or acetaminophen and the like.

The present invention provides a solid composition comprising the following components: (a) bromhexine or a salt thereof; (b) a nonionic surfactant; and (c) a compound selected from the group consisting of vitamin antioxidants, phenolic antioxidants, meloxicam, and acetaminophen (wherein R1 represents a hydrogen atom or a hydrogen atom). The pharmaceutical composition does not contain ibuprofen, clemastine fumarate, dihydrocodeine phosphate, noscapine, racemic methyephedrine hydrochloride, anhydrous caffeine, bromhexine hydrochloride, tranexamic acid, riboflavin, benfotiamine, ascorbic acid, hesperidin, D-mannitol, low-substitution-degree hydroxy propyl cellulose, crystalline cellulose, hydroxy propyl cellulose and polyoxyethylene hydrogenated castor oil 60, and the pharmaceutical composition can be used for preparing the pharmaceutical composition. The invention relates to a solid composition of hydroxypropyl methylcellulose, talc, hydroxy propyl cellulose and light anhydrous silicic acid.

The invention belongs to the field of drug delivery and oral preparations, and provides an 8-O-acetyl harpagide nano-composition and a preparation method thereof.The 8-O-acetyl harpagide-soybean lecithin compound is used as a nuclear phase, lactobionic acid and thioglycolic acid dual-modified chitosan and sodium tripolyphosphate are subjected to ionic crosslinking to form a shell layer, and the 8-O-acetyl harpagide nano-composition is prepared. Compared with the prior art, the freeze-dried powder has the advantages of high loading capacity, high solid content, low viscosity and wide processing window, small particle size, low polydispersity index and stable nano dispersion are obtained, ethanol residue and water content of the freeze-dried powder are reduced, freeze-dried storage stability, redissolution redispersibility and oral release and absorption performance are improved, and the freeze-dried powder is suitable for large-scale production. The method is suitable for the development of oral preparations for preventing the acetaminophen-induced liver injury.

1. Name of the designed product: medicine packing box (compound paracetamol tablet (II)). 2. Use of the designed product: medicine packing box. 3. Design points of the designed product: the pattern. 4. Picture or photo best indicating the design points: front view.

This invention discloses an Acinetobacter DL27 strain and its application in the degradation of acetaminophen, belonging to the field of microbial technology. This strain is deposited at the China General Microbiological Culture Collection Center (CGMCC) with accession number CGMCC No. 38039, deposited on April 3, 2026, and taxonomically named Acinetobacter. Acinetobacter sp . This invention has screened a strain of Acinetobacter DL27 that can efficiently degrade acetaminophen, and it can efficiently degrade acetaminophen in wastewater from actual sewage treatment plants and agricultural soils, which has important application value in the bioremediation of acetaminophen in complex environments.

Described herein is a soft gel capsule comprising a filler material and a shell composition. The filler material may include an alkali metal salt of NSAID, acetaminophen, and does not include povidone. The shell composition may include a film-forming material. The determined stability of the soft gel capsule at room temperature after 12 months may be at least about 99%.

The present invention relates to an aqueous pharmaceutical suspension composition having from about 0.2% to 20% of a substantially water soluble pharmaceutical active, e.g. acetaminophen; a suspension stabilizing effective amount of xanthan gum and microcrystalline cellulose; an effective amount of taste masking compositions; and water, as well as a process for producing such aqueous pharmaceutical suspensions.

The invention relates to the technical field of biological pharmacy, in particular to application of a rhizoma polygonati extract in preparation of a medicine for treating liver injury, and the rhizoma polygonati extract is prepared from the following main active ingredients: hexadecanamide, L-valine, 2-pyrrolidine carboxylic acid, 4-oxoproline, manninotriose, succinic acid, choline, D-(-)-ribose, stachyose and L-threonine. The invention proves that the prophylactic administration of the rhizoma polygonati extract can improve the acetaminophen-induced liver injury, so that the rhizoma polygonati extract has important clinical significance on pain patients who need to take acetaminophen for a long time, and can be developed into an effective liver protection auxiliary medicine.

To provide a solid composition containing ibuprofen in which changes in properties are suppressed. [Solution] The following components: (A) Ibuprofen, (B) At least one selected from the group consisting of tipepidine and its salts, A solid composition comprising (C) at least one selected from the group consisting of glycine, silicon dioxide, and acetaminophen, wherein the mass ratio of component (A) to (C) is 1:0.3 to 1:3 ((A):(C)) and the mass ratio of component (B) to (C) is 1:0.3 to 1:3 ((B):(C)).

The invention provides a method for detecting the content of a compound paracetamol and amantadine hydrochloride capsule, and relates to the field of pharmaceutical analysis. The method for detecting the content of the compound paracetamol and amantadine hydrochloride capsule comprises the following steps: (1) taking the content of the compound paracetamol and amantadine hydrochloride capsule, grinding, precisely weighing, putting into a container, adding water for dissolving, diluting to a constant volume, uniformly shaking, filtering, precisely measuring a continuous filtrate, titrating by using a silver nitrate titration solution to the end point by using a potentiometric titration method, and taking out the filtrate to obtain the content of the compound paracetamol and amantadine hydrochloride capsule. Calculating the content of amantadine hydrochloride in the compound paracetamol and amantadine hydrochloride capsule; and (2) taking the content of the compound paracetamol and amantadine hydrochloride capsule, grinding, precisely weighing, placing in a container, adding hydrochloric acid and first water, heating and refluxing, cooling to room temperature, adding second water, inserting the tip of a burette under the liquid level, quickly titrating to the end point by using a sodium nitrite titration solution by using a potentiometric titration method, and calculating the content of paracetamol in the compound paracetamol and amantadine hydrochloride capsule. The detection method provided by the invention has the advantages of good reproducibility, rapidness and no pollution in the detection process.

The application discloses a 7-azaindole photoacoustic imaging probe for detecting superoxide anion, a preparation method and application, and the photoacoustic imaging probe is named AIH-OTF, which is a blue-green solid prepared from methyl trifluoromethanesulfonate, dye AIH-OH and the like; the AIH-OTF realizes high-contrast PA imaging of endogenous superoxide anion in living cells, and in-situ evaluation of occurrence and repair of acetaminophen-induced liver injury is also determined through non-invasive monitoring of the PA reaction of AIH-OTF to superoxide anion; the AIH-OTF probe can be used as a useful tool for accurately diagnosing drug-induced liver injury in vivo. The photoacoustic imaging probe can realize real-time detection of in-vivo superoxide anion through AIH-OTF and the ability of diagnosing DILI; the cell toxicity is small, the biological compatibility is good, and the photoacoustic imaging probe can be used for in-vivo imaging of occurrence and repair of DILI.

1. Name of the product in this design: Packaging Bottle (Acetaminophen). 2. Intended use of this design: for pharmaceutical packaging. 3. The key design elements of this product are the combination of shape, pattern, and color. 4. The image or photograph that best illustrates the design's key points: 3D view 1. 5. The design for which protection is sought includes color.

The invention discloses application of S100A11 as a diagnostic marker and a therapeutic target for acute liver injury caused by acetaminophen, and belongs to the technical field of biological medicine. Aiming at the problem that the acute liver injury caused by acetaminophen (APAP) lacks a specific diagnostic marker and a therapeutic target, the invention discovers and verifies the specific high expression of S100A11 in the APAP liver injury for the first time. On the basis, the invention provides application of S100A11 as a biomarker in preparation of products for diagnosing APAP liver injury and application of S100A11 as a therapeutic target in preparation of drugs for preventing and / or treating APAP liver injury. Specifically, the acute liver injury caused by APAP can be effectively relieved by inhibiting the expression or activity of S100A11 (such as siRNA, an antibody or a small molecule compound). The invention provides a brand new scheme for noninvasive early diagnosis and targeted therapy of APAP liver injury, and has important clinical application value.

The present disclosure relates to liquid formulations containing acetaminophen and ibuprofen. In particular, the present disclosure relates to liquid formulations comprising acetaminophen, ibuprofen, and a sulfite compound. Such liquid formulations are suitable for parenteral (e.g., intravenous) administration. The present disclosure also relates to terminally-sterilized acetaminophen / ibuprofen liquid formulations. The present disclosure also relates to methods of treating patients by administration of such formulations and polymeric infusion containers, including flexible polymeric infusion containers, containing such formulations.